<DOC>
	<DOCNO>NCT02653482</DOCNO>
	<brief_summary>The primary purpose study evaluate impact dapagliflozin , compare placebo , heart failure disease-specific biomarkers , symptom , health status , quality life patient type 2 diabetes chronic heart failure reduce systolic function .</brief_summary>
	<brief_title>Dapagliflozin Effect Symptoms Biomarkers Diabetes Patients With Heart Failure</brief_title>
	<detailed_description>A 12-week randomized , double-blind , placebo-controlled trial evaluate effect once-daily dapagliflozin 10 mg heart failure disease-specific biomarkers ( BNP NTproBNP ) , symptom , health status , quality life patient type 2 diabetes chronic heart failure reduce systolic function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Documented type 2 diabetes least 6 month , treat least one glucoselowering medication ( oral , noninsulin injectables , insulin ) stable dose ( ) 12 week prior enrollment 2 . Hemoglobin A1c 6.511.0 % enrollment 3 . Established diagnosis NYHA Class II Class III heart failure ( LVEF≤40 % due either ischemic nonischemic etiology ) reduce systolic function least 16 week prior enrollment 4 . No change diuretic management least 2 week prior enrollment 5 . BNP ≥125 pg/mL and/or NTproBNP ≥ 600 pg/mL enrollment 1 . History type 1 diabetes 2 . Estimated glomerular filtration rate ( eGFR ) &lt; 45 enrollment 3 . Hospitalization heart failure within 60 day prior enrollment 4 . Admission acute coronary syndrome ( STelevation MI , nonSTelevation MI , unstable angina ) , percutaneous coronary intervention , cardiac surgery within 60 day prior enrollment 5 . Admission cardiac resynchronization therapy ( CRT ) within 90 day prior screen visit 6 . Planned cardiovascular revascularization ( percutaneous intervention surgical ) major cardiac surgery ( coronary artery bypass grafting , valve replacement , ventricular assist device , cardiac transplantation , surgery require thoracotomy ) within 90 day enrollment 7 . Patients volume deplete base upon physical examination time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>119 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>heart failure</keyword>
	<keyword>dapagliflozin</keyword>
	<keyword>SGLT-2 inhibitor</keyword>
</DOC>